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ABSTRACT
Purpose: To describe the baseline, 1 hr and delta high sensitivity cardiac troponin (hs-cTnT) values in
patients with suspected acute myocardial infarction (AMI) but without a final acute coronary syndrome
(ACS) diagnosis.
Materials and methods: hs-cTnT assay for RAPID rule out of acute myocardial infarction (TRAPID-AMI)
was a prospective diagnostic trial that enrolled emergency department (ED) patients with suspected
AMI. Final patient diagnoses were adjudicated by a clinical events committee and subjects placed in
different clinical groups: AMI, unstable angina, non-ACS cardiac, non-cardiac and unknown origin. The
baseline, 1 hr and delta hs-cTnT values were analysed in the 902 non-ACS patients.
Results: Amongst the 1282 studied the patient groups were 213 (17%) AMI, 167 (13%) unstable
angina, 113 (9%) non-ACS cardiac, 288 (22%) non-cardiac and 501 (39%) unknown origin. The hs-cTnT
values in the non-cardiac and unknown origin groups were combined. The median hs-cTnT values
(ng/L) were higher (p< 0.001) in the non-ACS cardiac compared to the non-cardiac/unknown origin
group at baseline (11.8,<5) and 1 hr (12.3,<5). Their negative predictive values were 0.955 (baseline)
and 0.954 (1 hr) for predicting non-ACS cardiac versus non-cardiac/unknown origin diagnoses.
Conclusions: Hs-cTnT may help predict whether non-ACS ED patients have a final non-ACS cardiac or
non-cardiac/unknown origin diagnoses.
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Context
Approximately 5%–10% of all emergency department (ED)
visits are for possible acute myocardial infarction (AMI)
(Goodacre et al. 2005). Thus, in the United States (US) 8–10
million patients are evaluated yearly in the ED with symp-
toms that might indicate the presence of an acute coronary
syndrome (ACS) (Owens et al. 2010). However, up to 85% of
these patients are ultimately diagnosed with a variety of
non-ACS diagnoses (Hollander 1999, Chase et al. 2006,
Pollack et al. 2006). There have been advances in technology
that have increased the sensitivity of troponin assays with
measurements reported below the 99th percentile (99th %)
in over 50% of an apparently normal healthy reference popu-
lation (Apple and Collinson 2011).
For the Roche high sensitivity cardiac troponin T (hs-cTnT)
assay (Diagnostics Elecsys) the 99th % is 14 ng/L, the level of
detection (LoD) 5 ng/L and the level of blank (LoB) 3 ng/L. The
LoB is defined as the mean observed result plus 1.645 stand-
ard deviations when testing a sample containing no analyte.
The LoD is defined as the LoB plus 1.645 standard deviation of
results obtained from a low concentration sample and is thus
the lowest troponin concentration that might reasonably be
distinguished from the LoB (Armbruster and Pry 2008). The hs-
cTnT assay has been reported in recent clinical trials to be use-
ful in the ruling out of AMI using a single baseline draw if the
result is below the LoD with no associated ECG ischemia
(Carlton et al. 2015, Body et al. 2016). Additionally, the use of
the baseline, 1 hr and resultant delta hs-cTnT measurements
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have been shown to be helpful in the very early rule in and
out of AMI (Reichlin et al. 2012, Mueller 2012, Roffi et al. 2015).
Troponin measurements are commonly ordered in US EDs
(14% of patients) and all abnormal values reported are those
above the 99th %.value for the contemporary assays cur-
rently utilized (Meigher et al. 2016). However, emergency
physicians in the US will be seeing in the future very low hs-
cTnT measurements (<99th %) reported, mostly in those
patients who have been ruled out for ACS (the vast majority
of those evaluated). There have been no studies to date ana-
lysing how these hs-cTnT values might be used to aid in
making correct patient diagnoses.
Objectives
The objectives of this analysis were to describe the baseline,
1 hr and the resultant delta hs-cTnT values in ED patients
enrolled in the hs-cTnT assay for RAPID rule out of AMI
(TRAPID-AMI) trial and not having a final diagnosis of an ACS
and to determine how these measurements might be used
clinically to clarify patients’ diagnoses. It was hypothesized
that non-ACS-diagnosed patients having other cardiac dis-
eases would have higher hs-cTnT levels than those with
those with non-cardiac or unknown origin diagnoses.
Clinical significance
 With advances in technology hs-cTn levels below the 99th
percentile will be reported in the majority of patients. The
authors have analyzed the high sensitivity troponin (hs-
cTn) T results in the TRAPID-AMI study in those patients
NOT having a final acute coronary syndrome diagnosis.
This paper is an initial analysis of this hs-cTnT data and
makes preliminary conclusions and recommendations on
how these measurements might be used clinically. Future
hs-cTn trials should carefully document the comorbidities
of all enrolled individuals as these will affect the hs-cTn
values that are measured and what they might mean.
Materials and methods
Design and setting
This prespecified sub-study of the TRAPID-AMI trial (a pro-
spective international multicentre diagnostic study conducted
in 12 sites on 3 continents (Mueller et al. 2012, Reichlin et al.
2012)) was conducted to describe and evaluate the hs-cTnT
values in patients who did not have a final ACS diagnosis.
TRAPID-AMI was undertaken to externally validate the diag-
nostic accuracy of the hs-cTnT baseline and 1-hr algorithm
for rapid rule in and out of AMI and thereby confirm its suit-
ability for routine clinical use in the ED (Reichlin et al. 2012,
Body et al. 2016).
Data collection and processing
Patients (>18 years of age) presenting to the ED with chest
discomfort suggestive of AMI and onset within 6hr of presen-
tation or peaking within this time period were eligible to par-
ticipate. Excluded patients included those on haemodialysis,
with acute trauma, receiving cardioversion, defibrillation or
thrombolytic before inclusion, having coronary artery bypass
grafting within the previous month, patients hospitalized with
AMI within the prior 3weeks, pregnant or breastfeeding
women and those who had been previously been included in
the study. Patients were enrolled in TRAPID-AMI once only. A
threshold of <6hr of symptoms was chosen in order to enrich
the study population with early presenters. All participants
provided written informed consent before enrolment, each
participating institution obtained approval from the appropri-
ate research ethics committee or institutional review board
and the trial was conducted in accordance with the principles
of the Declaration of Helsinki.
Patients underwent routine clinical assessments that
included history, physical examination, and 12 lead ECG, blood
testing and chest X-ray as per local practice. Clinical data were
recorded in study-specific case report forms. Baseline blood
samples were collected in ethylenediaminetetracetic acid
plasma tubes within 45min of ED arrival or within 45min of
initial physician assessment. Additional blood samples were
obtained after 1 hr (±30min), 2 hrs (±30min) and 4–14hrs
(±30min). Within 30min of blood collection, the samples were
centrifuged at 2500g for 15min, plasma was separated and
within 4 hrs of collection aliquots were frozen at 80 C. They
were later assayed in a core laboratory in a blinded fashion
for hs-cTnT with the Roche Diagnostics Elecsys 2010 (99th %
14ng/L, coefficient of variation <10% at 13ng/L, LoD 5ng/L)
and sensitive troponin I (s-cTnI) using the Siemens Healthcare
ADVIA Centaur (99th % 40ng/L, coefficient of variation <10%
at 30ng/L, LoD 6ng/L).
Outcomes
To determine the final diagnosis causing the symptoms for
each patient adjudication was performed by a clinical events
committee comprised of two independent cardiologists with a
third one used if there was disagreement. Patients were placed
in 1 of 5 clinical groupings after review of all available medical
records pertaining to the patient from ED presentation to 30-
day follow-up. The first group included those with AMI, diag-
nosed according to the universal definition of AMI (Thygesen
et al. 2012, Meigher et al. 2016). The s-cTnI assay was used for
this adjudication (the ED physicians did not have access to
these values) and there was complete blinding to hs-cTnT lev-
els during the study period. The other predefined clinical
grouping included unstable angina, non-ACS cardiac disease,
non-cardiac disease and symptoms of unknown origin.
Given that the diagnosis of unstable angina utilized for this
study was predominately made using clinical assessments
(typical angina at rest, a deterioration of previously stable
angina, a positive result on cardiac exercise testing, a cardiac
catheterization showing stenosis of >70% or more of vessel
diameter or when the patient had an AMI or sudden unex-
pected cardiac death within 30 days of study inclusion) we
chose to look at the hs-cTnT levels in the non-ACS-diagnosed
groups (non-ACS cardiac, non-cardiac and unknown origin).
Statistical analysis
Categorical data were summarized with frequencies and per-
centages and continuous data by the mean and standard
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deviation (for normal data) and median and interquartile
range (for non-normal data). Overall comparisons of the car-
diac, non-cardiac and unknown origin patient groups were
performed using the Chi-square test for categorical data,
one-way analysis of variance for normally distributed continu-
ous data and the Kruskal–Wallis test for non-normally distrib-
uted continuous data. The hs-cTnT measurements at
baseline, 1 hr and the resulting delta values between the car-
diac and non-cardiac/unknown origin groups were compared
using the Wilcoxon Rank Sum test. ROC curves were plotted
and the area under these curves used to evaluate the ability
of hs-cTnT at baseline and 1 hr to predict a non-ACS cardiac
diagnosis from the non-cardiac/unknown aetiology group.
The optimal cut points for hs-cTnT at baseline and 1 were
defined as those resulting in the maximum sum of the sensi-
tivity plus specificity. The corresponding sensitivity, specificity
and negative and positive predictive values were determined.
Results
From August 2011 to June 2013, 1458 patients with sus-
pected AMI were enrolled of whom 1282 had sufficient data
for inclusion in this analysis (Mueller 2012). The median time
from symptom onset or peak to ED arrival was 2.7 hr (inter-
quartile range 1.5–5.1 hr) and the median time to first study
blood draw was 3.4 hr (interquartile range 2.1–6.0 hr).
Clinically available data for each of the 3 non-ACS groups are
compared in Table 1. While the non-ACS cardiac patients
were significantly older with a more frequent history of
hypertension (HTN), diabetes, smoking, myocardial infarction,
congestive heart failure and had higher diastolic blood pres-
sure, heart rate and sinus rhythm there was overlap in these
variables within the non-cardiac and unknown origin groups.
The adjudicated final diagnosis in the clinical groups
described was as follows: 213 (17%) AMI, 167 (13%) unstable
angina, 113 (9%) non-ACS cardiac, 288 (22%) non-cardiac and
501 (39%) unknown origin. A more detailed breakdown of
the diagnostic categories of the non-ACS cardiac group is
shown in Figure 1. The majority of these patients (88%) were
diagnosed with arrhythmia, HTN crisis and acute heart failure
(AHF). A similar more detailed breakdown of the diagnostic
categories of non-cardiac and unknown origin diagnosis is
shown in Figure 2. Most of these patients (64%) had an
unknown origin and for the non-cardiac group the majority
(34%) had musculoskeletal, gastrointestinal, anxiety and
chronic obstructive lung disease (COPD) etiologist as causes
for their symptoms.
The distributions for the hs-cTnT values were initially com-
pleted for the non-ACS cardiac, non-cardiac and unknown ori-
gin groups. However, the non-cardiac and unknown origin
groups had similar boxplots, quartiles and median values and
so their hs-cTnT values were pooled for statistical analysis. Hs-
cTnT measurements  LoD (5 ng/L) were found in 79.6% and
78.8% of patients with a non-ACS cardiac diagnosis and 37.4%
and 38.1% of those with a non-cardiac/unknown origin diag-
nosis at baseline and 1 hr, respectively. Figure 3 shows the dis-
tribution of the non-ACS cardiac and non-cardiac/unknown
origin groups’ hs-cTnT levels at baseline, 1 hr and the resultant
delta values. The median hs-cTnT measurements between
Table 1. Non-ACS group clinical variables comparisons.
Non-ACS Diagnosis Group
Variable Cardiac (N¼ 113) Other (N¼ 288) Unknown (N¼ 501) Overall Comparison P-value
Age 65.9 ± 16.0 69.0 57.9 ± 14.9 57.0 58.6 ± 14.2 57.0 <0.001
Male Gender 72 (63.7%) 166 (57.6%) 286 (57.1%) 0.427
Weigh in Kg 84.2 ± 21.1 82.0 81.3 ± 20.4 79.0 81.9 ± 17.8 79.0 0.389
Hx of Hypertension 90 (79.6%) 151 (52.4%) 278 (55.5%) <0.001
Hx of Diabetes 34 (30.1%) 45 (15.6%) 88 (17.6%) 0.003
Current Smoker 21 (18.6%) 81 (28.5%) 108 (22.0%) 0.048
Past Smoker 41 (36.3%) 82 (28.9%) 177 (36.0%) 0.105
Hx of MI 24 (21.2%) 45 (15.6%) 93 (18.6%) 0.365
Hx of CHF 20 (17.7%) 15 (5.2%) 33 (6.6%) <0.001
Hx of Cerebrovascular Disease 15 (13.4%) 25 (8.7%) 41 (8.2%) 0.218
Systolic Blood Pressure 143.5 ± 30.7 139.0 140.7 ± 21.7 139.0 142.1 ± 22.0 142.0 0.526
Diastolic blood pressure 85.2 ± 16.8 85.0 81.3 ± 13.5 81.0 81.5 ± 13.7 81.0 0.033
Heart rate 91.5 ± 24.1 87.0 77.7 ± 15.8 77.0 76.1 ± 13.6 75.0 <0.001
Creatinine reading 1.02 ± 0.64 0.88 0.86 ± 0.33 0.81 0.85 ± 0.29 0.81 0.004
Sinus rhythm 68 (60.2%) 273 (94.8%) 471 (94.0%) <0.001
Numeric data is shown as the means ± standard deviation with the median below.
Figure 1. Non-ACS cardiac diagnoses.
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these 2 groupings at baseline and 1 hr were significantly dif-
ferent (11.8, <5; 12.3, <5 ng/L; all p< .0001) while the delta
values were not (0.0, 0.0 ng/L; p¼ 0.609).
Receiver operator curves (ROCs) show that at baseline and
1 hr the areas under the curve (AUC) were 0.7653 (95% CI:
0.718–0.813) and 0.7672 (95% CI: 0.720–0814) with optimal
cut points of 5.49 and 5.35 ng/L, respectively, in differentiating
non-ACS cardiac from non-cardiac/unknown origin patients
(Figures 4 and 5). The negative predictive values (NPVs) for a
non-ACS cardiac diagnosis with values <5.49 ng/L (baseline)
and <5. 35 ng/L (hr 1) were 0.955 and 0.954, respectively.
Figure 2. Non-cardiac/unknown aetiology diagnoses.
Figure 3. Hs-cTnT measurements in the non-ACS cardiac and non- cardiac/unknown aetiology groups.
Figure 4. Prediction of non-ACS cardiac from non-cardiac/unknown aetiology
diagnosis at baseline.
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When the cut-off points for the ROC analyses were changed
to 5 ng/L (LoD) at baseline and 1 hr the sensitivities (0.796,
0.788), specificities (0.626, 0.619) and negative (0.956, 0.953),
and positive predictive (0.234, 0.228) values changed margin-
ally. The ROC analysis for the delta value between baseline
and 1 hr had an AUC of 0.486 indicating that the hs-cTnT lev-
els in these groups essentially remained very stable from
baseline to hr 1.
There were 23 patients (20%) who had hs-cTnT values
< LoD at baseline and had a final non-ACS cardiac diagnoses.
These included 11 patients with arrhythmia, 10 HTN crises
and 2 pericarditis. At 1 hr, 24 patients (21%) had values
below the LoD and of these 11 had arrhythmia, 11 HTN cri-
ses and 2 pericarditis.
Discussion
This is the first report, to our knowledge, describing the
measurements and possible clinical utility of hs-cTnT in
patients enrolled in a large diagnostic AMI clinical trial but
not having a final ACS diagnosis. This analysis is important as
emergency physicians in the US will see in the near future
many hs-cTnT levels reported that are below the 99th % in
patients that do not meet current criteria for the early rule
in/out of AMI and who are not thought clinically to have
unstable angina.
Patients in the non-ACS cardiac group (113% or 9% over-
all) had final diagnoses mostly comprised of arrhythmia
(43%), HTN crisis (25%) and AHF (20%) with a few having car-
diomyopathy, myocarditis, pericarditis and aortic dissection.
Patients in the non-cardiac group (288 or 23% overall) had
diagnoses mostly of musculoskeletal (17%), gastrointestinal
(10%), anxiety (6%) and COPD with a few having pneumonia,
sepsis, pulmonary embolus and malignancy. The unknown
origin group was the largest comprising 501% or 39% of
patients enrolled overall.
It can be difficult to determine clinically the diagnoses of
the non-ACS patients and how accurate that final provisional
ED diagnosis might be. Clinical assessments are utilized in
making these alternate diagnostic decisions but the use of
these alone do not reliably differentiate those with a non-ACS
cardiac diagnosis from those with a non-cardiac/unknown ori-
gin categorization (Table 1). We have shown that patients
with non-ACS cardiac disease have significantly (p< 0.001)
higher median hs-cTnT levels than those in the combined
non-cardiac/unknown origin group both at baseline and 1 hr.
Additionally, the optimal hs-cTnT level to differentiate these
groups at baseline was 5.49 and at 1 hr 5.35 ng/L. If the hs-
cTnT values are less than these there is a NPV for non-ACS car-
diac diagnosis of 0.955 at baseline and 0.954 at 1 hr. The NPVs
(0.956 at baseline, 0.953 at 1 hr) remained similar when the
LoD (5 ng/L) was used in the ROC analysis. Just as very low
baseline hs-cTnT levels (below the LoD) strongly suggest the
absence of AMI (Body et al. 2016) it appears that similar values
< LoD at baseline and 1 hr also suggest the absence of any
alternative other non-ACS cardiac diagnoses. Patients with hs-
cTnT levels below the LoD at either baseline or 1 hr are very
unlikely to have a non-ACS cardiac diagnosis as the cause of
the symptoms that brought them to the ED for evaluation,
especially if they have no comorbidities that are associated
with chronic troponin elevations. It is our thought that if all
patient comorbidities had been known and those patients
with a comorbidity that was associated with chronic hs-cTnT
elevations (HTN, heart failure or renal insufficiency) were
removed from the analysis then our NPVs at baseline and 1 hr
predicting those with non-cardiac/unknown origin might have
approached 100%. Our current results, although not definitive,
may be helpful to ED physicians on their choices of early diag-
nostic workups for individual patients presenting with sus-
pected ACS.
There were some patients with a final non-ACS cardiac
diagnosis that had hs-cTnT measurement below the LoD at
baseline and 1 hr (Figure 3). These were seen when the final
diagnosis was arrhythmia, HTN crisis and pericarditis but not
when the non-ACS cardiac diagnosis was AHF. This brings to
question as to whether these final individual patient diagno-
ses were correct and if so could the hs-cTnT value < LoD
indicate a less malignant arrhythmia, a hypertensive crisis
with no structural heart damage and thus management on
an outpatient basis, or possibly a benign case of pericarditis.
This report comprises a prespecified and preliminary
secondary analysis of the TRAPID-AMI study and hence
requires large prospective trials that enrol all suspected
ACS patients for verifications/alterations before our results
can be routinely clinically implemented. The final non-ACS
diagnoses provided by the adjudication committee were
based mainly on the work up completed by the treating
physicians and so the non-ACS diagnoses could have been
in some cases not accurate. While there were some clinical
variables (Table 1) that differed between the three non-
ACS diagnostic groups these were not further studied as
Figure 5. Prediction of non-ACS cardiac from non-cardiac/unknown aetiology
at 1 hr.
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our focus was on the potential use of hs-cTnT to differen-
tiate between the non-ACS cardiac and non-cardiac/
unknown origin groups. Future studies will require accurate
documentation of patients’ current comorbidities and
chronically measurable troponin levels as these were not
systematically recorded in TRAPID-AMI.
Conclusions
In ED patients being evaluated for possible ACS hs-cTnT meas-
urements will be reported in approximately 80% of those with
a final non-cardiac and 40% of individuals with non-cardiac/
unknown origin diagnoses. Hs-cTnT levels < LoD at baseline
and 1 hr may help in predicting whether these patients might
have a non-ACS cardiac versus a non-cardiac/unknown origin
cause for their symptoms. Also baseline and 1 hr levels of hs-
cTnT< LoD in patients having a non-ACS cardiac diagnosis
might help in determining the severity of that specific clinical
presentation. As there will be continued increasing use of hs-
cTnT testing in the US, ED setting further trials are necessary
to clarify how best to incorporate these very low levels into
the diagnostic and therapeutic approaches in patients who
are suspected of but not having an ACS diagnosis.
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